Venous thromboembolism

Lipocalin-2 Predicts Long-Term Outcome of Normotensive Patients with Acute Pulmonary Embolism

29 days ago   |   Springer

Abstract Normotensive patients with acute pulmonary embolism are accompanied by heterogeneously adverse events. Responding to tissue injury, lipocalin-2 is elevated in...
Read more ...

Agile Therapeutics Wins FDA Nod for Twirla Contraceptive Patch

Agile Therapeutics Wins FDA Nod for Twirla Contraceptive Patch

1 month ago   |   Xconomy

A contraceptive patch developed by Agile Therapeutics was awarded FDA approval late Friday, clearing the way for a new birth control option to reach the market. The Agile...
Read more ...

InGeneron Adds $23M to Test Stem Cell Therapy for Rotator Cuff Tears

InGeneron Adds $23M to Test Stem Cell Therapy for Rotator Cuff Tears

9 monthes ago   |   Xconomy

Houston - Stem-cell technology developer InGeneron has added another $23 million to a Series D financing it announced in 2017, bringing the total of the funding round to $43...
Read more ...

Assessment of central venous catheterization in a simulated model using a motion-tracking device: an experimental validation study

10 monthes ago   |   BMC Bioinformatics

Central venous catheterization is a basic requirement for many medical specialties. Simulated training in CVC may allow the acquisition of this competency but few reports have...
Read more ...

UFGI publication round-up week 4/22

11 monthes ago   |   Genetics Institute

Multi-phase distribution and risk assessment of endocrine disrupting chemicals in the surface water of the Shaying River, -Huai River Basin, China. Huang Y, Xie X, Zhou LJ, Ji...
Read more ...

New Phase 3 CASSINI Data Presented on the Use of XARELTO® for Venous Thromboembolism Prevention in High-Risk Cancer Patients

One year ago   |   San Diego Biotechnology   |   2 articles

VTE is the second leading cause of death in people with cancer SAN DIEGO, Dec. 4, 2018 /PRNewswire/ - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced...
Read more ...

Bluegrass Vascular Opens U.S. Clinical Trial for Obstructed Veins

Bluegrass Vascular Opens U.S. Clinical Trial for Obstructed Veins

2 years ago   |   Xconomy

San Antonio -Bluegrass Vascular Technologies has started to enroll patients in a U.S. clinical trial for its catheter system for regaining access to obstructed veins. Bluegrass...
Read more ...

MiR-411 suppressed vein wall fibrosis by downregulating MMP-2 via targeting HIF-1α

2 years ago   |   Springer

Abstract This study was aim to investigate the specific mechanisms of miR-411 in vein wall fibrosis remodeling. Vein wall fibrosis injury-induced deep venous thrombosis rat...
Read more ...

Cardiovate Adds $650K for Device Aiming to Replace Clogged Arteries

Cardiovate Adds $650K for Device Aiming to Replace Clogged Arteries

2 years ago   |   Xconomy

San Antonio - Medical device maker Cardiovate has closed a $1 million seed round of funding from an existing group of investors to help it begin a year-long animal study on a...
Read more ...

A Computational Model of the Biochemomechanics of an Evolving Occlusive Thrombus

2 years ago   |   Springer

Abstract Blood clots are fundamental to preventing excessive blood loss in cases of vascular injury and to promoting subsequent wound healing, but also to many disease...
Read more ...


Register you to post on BioTech Mag

Free Registration

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

The financial markets may remain volatile but Keros Therapeutics managed to raise more money in its public market debut than it had initially planned. Late Tuesday the... Read more ...

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

Gilead Sciences has signed an agreement with South San Francisco biotech Second Genome to use its microbiome drug development expertise to advance the compounds it is... Read more ...

Organovo Future Unclear After Shareholders Reject Tarveda Merger

Organovo Future Unclear After Shareholders Reject Tarveda Merger

A planned merger between struggling 3-D “bioprinter” Organovo and Tarveda Therapeutics, a privately held cancer drug developer looking to join the public markets through a... Read more ...

In Battle Against COVID-19 Pandemic, Scientists Turn to PacBio Sequencing

In Battle Against COVID-19 Pandemic, Scientists Turn to PacBio Sequencing

Image by Miroslava Chrienova from Pixabay Our team is proud to announce that PacBio has been working closely with customers to help in the fight against the COVID-19 pandemic... Read more ...

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

Some diseases have proven difficult to address using conventional tools of drug discovery that target disease-causing proteins. Roche is placing a $190 million bet on Arrakis... Read more ...

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA's OK to start testing its candidate in healthy volunteers. The... Read more ...

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to focus on clinical-stage compounds, including... Read more ...

Creating Consistent Value in Biotech Without Diluting Stakeholders

Creating Consistent Value in Biotech Without Diluting Stakeholders

One of the greatest challenges for pre-commercial biotech companies is consistently generating capital necessary for operating costs and for R&D of new products that provide... Read more ...

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

In the Boston biotech hub, much progress has been made advancing digital health, but significant scientific, technological, financial, and regulatory challenges remain. Join us... Read more ...

Methylation-driven model for analysis of dinucleotide evolution in genomes

CpGs, the major methylation sites in vertebrate genomes, exhibit a high mutation rate from the methylated form of CpG to TpG/CpA and, therefore, influence the evolution of... Read more ...